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Abstract
Background: Interferons alpha (IFNa) are the cytokines most widely used in clinical medicine for the treatment of
cancer and viral infections. Among the immunomodulatory activities possibly involved in their therapeutic efficacy,
the importance of IFNa effects on dendritic cells (DC) differentiation and activation has been considered. Despite
several studies exploiting microarray technology to characterize IFNa mechanisms of action, there is currently no
consensus on the core signature of these cytokines in the peripheral blood of IFNa-treated individuals, as well as
on the existence of blood genomic and proteomic markers of low-dose IFNa administered as a vaccine adjuvant.
Methods: Gene profiling analysis with microarray was performed on PBMC isolated from melanoma patients and
healthy individuals 24 hours after each repeated injection of low-dose IFNa, administered as vaccine adjuvant in
two separate clinical trials. At the same time points, cytofluorimetric analysis was performed on CD14
+ monocytes,
to detect the phenotypic modifications exerted by IFNa on antigen presenting cells precursors.
Results: An IFNa signature was consistently observed in both clinical settings 24 hours after each repeated
administration of the cytokine. The observed modulation was transient, and did not reach a steady state level
refractory to further stimulations. The molecular signature observed ex vivo largely matched the one detected in
CD14
+ monocytes exposed in vitro to IFNa, including the induction of CXCL10 at the transcriptional and protein
level. Interestingly, IFNa ex vivo signature was paralleled by an increase in the percentage and expression of
costimulatory molecules by circulating CD14
+/CD16
+ monocytes, indicated as natural precursors of DC in response
to danger signals.
Conclusions: Our results provide new insights into the identification of a well defined molecular signature as
biomarker of IFNa administered as immune adjuvants, and for the characterization of new molecular and cellular
players, such as CXCL10 and CD14
+/CD16
+ cells, mediating and possibly predicting patient response to these
cytokines.
* Correspondence: eleonora.arico@iss.it
1Department of Cell Biology and Neurosciences Istituto Superiore di Sanità,
Rome, Italy
Full list of author information is available at the end of the article
Aricò et al. Journal of Translational Medicine 2011, 9:67
http://www.translational-medicine.com/content/9/1/67
© 2011 Aricò et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.Background
Interferons alpha (IFNa) are still the cytokines most
widely used in clinical medicine today, with applications
both in oncology and in the treatment of certain viral
infections [1]. Several decades of research on IFNa have
revealed that these cytokines exert immunomodulatory
activities possibly involved in their in vivo therapeutic
efficacy, spanning from the differentiation of the Th1
subset, the generation of CTL and the promotion of
Tc e l lin vivo proliferation and survival [reviewed in ref.
[2]]. In particular, IFNa have proved to play an impor-
tant role in the differentiation of monocytes into dendri-
tic cells (DC) and in enhancing DC activities [3-8]. It
has been suggested that IFNa-mediated DC activation
can represent one of the mechanisms underlying the
cytokine therapeutic efficacy in vivo [2].
In the attempt to understand in more detail the
mechanisms of IFNa in vivo, several studies have
recently utilized microarray technologies to detect and
analyze an IFNa-specific signature in the peripheral
blood cells of IFNa-treated individuals, with particular
focus on HCV and melanoma patients [9-15]. These
studies have revealed that many interferon-stimulated
genes [16] (ISG), previously known to be induced by
this cytokine in other animal or human in vitro settings,
can be found up-regulated in the blood of patients trea-
ted in vivo with the cytokine. Furthermore, novel and
unexpected ISG were added to the list of possible in
vivo mediators of IFNa immunomodulatory and/or anti-
tumor activity [9-15]. Defining with acceptable accuracy
the pool of genes considered to be the signature of
IFNa in vivo helps to understand the involvement of
this cytokine in clinical as well as therapeutic settings
[17,18]. Notably, an IFNa signature has been observed
in systemic lupus erythematosus (SLE) patients, suggest-
ing that the overexpression of a specific set of genes can
represent the hallmark of in vivo cell exposure to IFNa,
which is commonly detected in the sera of these
patients [19]. More recently, the presence of a promi-
nent IFNa signature has been reported in patients
experiencing a growing list of autoimmune disorders,
including psoriasis, multiple sclerosis, rheumatoid arthri-
tis, dermatomyositis, primary biliary cirrhosis and insu-
lin-dependent diabetes mellitus [20]. These data,
together with the autoimmune-like phenomena reported
in melanoma patients responding to IFNa therapy [21],
confirmed the involvement of this cytokine in the deli-
cate balance between immunity and autoimmunity.
Besides helping to gain insight into IFNa mechanisms
of action in vivo, identifying a clear-cut IFNa signature
ex vivo opens the possibility to define patterns of gene
expression profiles significantly associated with IFNa
treatment efficacy. In turn, this may also provide
insights into candidate predictor biomarkers of response
to therapy, and possibly assist in making the appropriate
therapeutic decisions when a patient does not present
with a favorable response profile. In spite of many
efforts performed in this direction, the literature in this
field suffers from a lack of consistency among the
results obtained from patients suffering from different
diseases and receiving different IFNa preparations. The
majority of these studies have been performed in
patients chronically infected with HCV, while attempt-
ing to identify a consensus blood biomarker predictive of
IFNa/Ribavirin efficacy in patients blood [9-12,15].
Since it is known that the pattern of PBMC gene
expression in HCV patients is altered by the infection
itself [15], IFNa-induced modulations observed in these
patients may be somehow related to the HCV disease,
and possible affected by individual-specific variability,
thus providing little information on the general mechan-
isms of action of the cytokine per se.
Despite the accumulating information on the IFNa-
induced genes and of their possible in vivo role, little is
known about the consistency of the IFNa signature in
healthy vs cancer patients. A still elusive area of investi-
gation is the kinetics of gene up-regulation in correla-
tion with the possible appearance of immune cells
elicited by IFNa and playing a primary role in the biolo-
gical responses of IFNa-treated cancer patients. Like-
wise, no information is currently available on the
transient and long-term effect of low doses of IFNa
used with modalities typical of a vaccine adjuvant, as
IFNa, in spite of their now recognized role as natural
links between innate and adaptive immunity [2], have
been extensively and generally used in clinics as typical
antiviral or antitumor drugs. As a matter of fact,
although the more effective and better tolerated pegy-
lated IFNa2b is now widely used for the therapy of
HCV infection [22] and in the adjuvant melanoma set-
ting [23], no study is currently available on the clinical
use of this molecule administered as vaccine adjuvant.
In the present study, we utilized PBMC derived from
melanoma patients and healthy individuals, who had
been enrolled in two clinical trials with similar treat-
ment schedule, aimed at assessing the role of IFNa
administered as vaccine adjuvant. We exploited microar-
ray technology to evaluate and compare the modulations
of PBMC global gene expression profiles induced by
IFNa in melanoma and normal donors. The effects of
the administration of different doses of IFNa, as well as
of repeating the administration of the cytokine in suc-
cessive treatment cycles, were evaluated. The kinetics
and the biological significance of the modulations
observed at the transcriptional level were correlated
with the phenotypic changes observed in circulating
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+ and CD14
+/CD16
+ monocytes. The overall
results provide new insights in the identification of spe-
cific biomarkers for adjuvant IFNa and in the character-
ization of new molecular and cellular players mediating
the response to this cytokine in patients.
Methods
Samples collection for gene profiling analysis from
subjects receiving IFNa
PBMC for gene profiling analysis were obtained from
patients enrolled in two studies sponsored by the Isti-
tuto Superiore di Sanità Rome, Italy. Both studies were
approved by the Internal Review Board of the Istituto
Superiore di Sanità and the clinical centers involved.
Only subjects who have given informed written consent
before initiating the trial were admitted to participate to
the studies. In the first study, HLA-A*0201
+ stage IV
metastatic melanoma patients underwent four cycles of
vaccinations with gp100:209-217(210 M), IMDQVPFSV
and Melan-A/MART-1 Melan-A/MART-1:26-35(27L),
ELAGIGILTV melanoma peptides, given in combination
with 3 million units (MU) of IFNa administered the
previous day, in concomitance and the following day of
the peptides inoculation [24]. The peptides were pre-
pared under Good Manufacturing Practice conditions by
Clinalfa (Laufelfingen, Switzerland) and were supplied as
a water-soluble white powder in vials containing 250 μg
of peptide. IFNa (human leukocyte IFNa; Alfaferone)
was supplied by Alfawassermann (Bologna, Italy).
For gene profiling analysis on PBMC, blood was col-
lected from six patients before any treatment (T0 and T42)
and 24 hours after the IFNa plus peptide administration
(T2 and T44). PBMC collections for gene profiling coin-
cided with the first and the fourth vaccination (see Addi-
tional data file 1 for the complete treatment schedule).
For the second clinical study, healthy subjects pre-
viously unvaccinated against HBV were randomly
divided into three groups to receive the HBV Engerix-B
vaccine plus saline placebo or the HBV vaccine in asso-
ciation with human leukocyte IFNa (Alfaferone) at the
dose of 1 or 3 MU [25]. Commercial pack of one mono-
dose vial of Engerix-B (SmithKline Beecham), 20 μg/ml
dose, was provided free of charge by Alfa Wassermann
together with the IFNa and the placebo ampoules. The
vaccination course was the standard 3-dose regimen
administered at time zero (T0, baseline), one and six
months later (T1 and T6m), in the placebo group, and
two doses at T0 and T1m in the IFNa-treated groups.
Blood samples were collected from 10 subjects per
group for gene profiling analysis before (T0, T1m) and
24 hours after the placebo or IFNa plus vaccine admin-
istration (T0+24, T1m+24), and the collection was
repeated on the first and the second cycle of vaccination
(Additional data file 1).
The microarray data sets obtained from the two clinical
trials were analyzed separately. For blood collection, 10 ml
of peripheral blood was collected into BD vacutainer™
CPT™/sodium heparin tube and processed for the separa-
tion of mononuclear cells from whole blood according to
the manufacturer’s instruction. The recovered mononuc-
lear cells were washed three times with PBS and resus-
pended in lysis buffer for RNA isolation (RNeasy, Qiagen).
In vitro studies
PBMC were obtained by apheresis from 5 healthy
donors at the Department of Transfusion Medicine,
NIH. Total PBMC or the CD14
+ fraction (purity >98%
as assessed by flow cytometry) isolated by column
magnetic immunoselection (MACS Cell Isolation Kits;
Miltenyi Biotec), were plated at the concentration of 2 ×
10
6 cells/ml in OPTI-MEM medium (Gibco), and
cultured at 37ºC and 5% CO2 in the presence of either
IFNa2b (Intron A) or IFNg1b (Actimmune) at the con-
centration of 1,000 U/ml. Cells were harvested and lysed
in RLT buffer (Qiagen) and culture supernatants were
collected for proteomic analysis 8 and 24 hours after
stimulation respectively.
RNA isolation and amplification and cDNA arrays
Total RNA was isolated using RNeasy mini kits (Qia-
gen). Amplified antisense RNA (aRNA) was prepared
from total RNA (0.5-3 μg) according to a previously
described protocol [26]. For hybridization to the micro-
arrays, test samples were labeled with Cy5-dUTP
(Amersham, Piscataway, NJ), and reference samples
(pooled normal donor PBMC) were labeled with Cy3-
UTP. Test-reference sample pairs were mixed and co-
hybridized overnight to microarray slides in humidifying
chambers. Test-reference sample pairs were mixed and
co-hybridized to 17 K-cDNA microarrays. Microarrays
were printed in house at the Immunogenetics Section,
Department of Transfusion Medicine, Clinical Center,
NIH, with a configuration previously described [27].
Hybridized arrays were scanned at 10-micrometer reso-
lution on a Gene-Pix 4000 scanner (Axon Instruments,
Downingtown, PA) at variable PMT voltage to obtain
maximal signal intensities with less than 1% signal
saturation. Resulting jpeg and data files were analyzed
via mAdb Gateway Analysis tool [http://nciarray.nci.nih.
gov]. The raw data set were filtered according to stan-
dard procedure to exclude spots with minimum inten-
sity (arbitrarily set to < 200 in both fluorescence
channels) or with diameters < 25 μm. Lowess intensity
dependent normalization was used to adjust for differ-
ences in labeling intensities of the Cy3 and Cy5 dyes.
The adjusting factor varied over intensity levels. All sta-
tistical analyses were done using the log2-based ratios.
All analyses related to class comparison was done using
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Tools.html] developed by R. Simon et al [28]. Genes that
were differentially expressed among the two classes were
identified using a random-variance t-test [29]. Genes were
considered statistically significant if their p value was <
0.001 and further analyzed by Cluster and Tree View soft-
ware [30]. No adjustment was made for multiple compari-
sons. Gene annotations were mined using web-based tools
such as DAVID [http://david.abcc.ncifcrf.gov/], GeneCards
[http://www.genecards.org/index.shtml], COPE [http://
www.copewithcytokines.de]. A modified Fisher Exact test
was used for gene-enrichment analysis on Gene Ontology
classification (by DAVID [http://david.abcc.ncifcrf.gov/]).
Gene ratios are presented according to the central method
for display [31].
Quantitative PCR
QPCR was applied to detect the expression of BAFF,
CXCL-10 and Mx transcripts using an ABI Prism 7900
HT (Applied Biosystems, Foster City, CA, USA). Primers
and probes were custom-designed to span exon-intron
junctions and generate < 150 base-pair amplicons (Bio-
source, Camarillo, CA, USA). Taqman probes were
l a b e l e da tt h e5 ’ and 3’ ends with the reporter FAM (6-
carboxyfluorescein; emission lmax =5 1 8n m )a n dt h e
quencher TAMRA (6-carboxytetramethylrhodamine;
emission lmax = 582 nm), respectively. Standard curves
were based on amplicons generated from PBMC exposed
in vitro to IFNa2b (1,000 IU/ml); copy numbers were
estimated with Oligo Calculator [http://www.pitt.edu/
~rsup/OligoCalc.html]. Linear regression R
2-values perti-
nent to all standard curves were ≥ 0.98. QPCR reactions
were conducted in a 20 μl volume, including 1 μlc D N A ,
1× Taqman Master MIX (Applied Biosystems), 2 μlo f
20 μM primer and 1 μl of 12.5 μM probe. Thermal cycler
parameters included 2 minutes at 50°C, 10 minutes at
95°C and 40 cycles involving denaturation at 95°C for
15 s, annealing-extension at 60°C for 1 minute. cDNA
copy numbers were normalized according to the expres-
sion of Beta Actin as endogenous housekeeping gene [32].
Cytofluorimetric analysis of monocytes ex vivo
For cytofluorimetric analysis, 30 ml of peripheral blood
were collected into Vacutainer vials (Becton Dickinson)
containing ACD as anticoagulant at each designated
t i m ep o i n tf r o md o n o r se n r o l l e di nt h eH B Vs t u d y .
Blood was diluted 1:1 with sterile PBS then separated by
Ficoll-Hypaque (Pharmacia,) density gradient to obtain
PBMC. PBMC were washed twice, counted using Try-
pan Blue exclusion method, centrifuged again, resus-
pended at 30 × 10
6 cells/ml in 90% heat-inactivated
foetal calf serum plus 10% DMSO and frozen in a -80°C
freezer until shipment. Samples were shipped in dry ice.
On arrival at the ISS, the vials were transferred into a
liquid nitrogen tank. Samples of a single donor for each
time-point (T0, T0+24, T1 and T1+24) were thawed
and processed simultaneously. Number of viable cells
was evaluated by trypan-blue exclusion method. 10 mil-
lions PBMC were incubated in presence of FcR Blocking
Reagent (Miltenyi) to avoid not-specific staining, then
treated with Dead Cell Discriminator Reagent (Miltenyi)
and finally stained, in presence of Foetal Calf Serum and
Sodium Azide, with fluorochrome-conjugated mAbs
for 20 min at 4°C. The following mAbs were used:
APC-conjugated anti-CD14, PE-conjugated anti-CD16,
FITC-conjugated anti-HLA-DR (Becton Dickinson),
FITC-conjugated anti-CD40 and anti-CD86 (Pharmin-
gen). Samples were collected and analyzed by using a
FACSCalibur (Becton Dickinson) and data analysis was
performed by FlowJo software (Tree-Star), excluding
dead cells and including cells falling in the expected
morphological gate. The band pass filter used for cyto-
fluorimetric analysis was 525 nanometers for FITC, 575
nanometers for PE and 675 nanometers for APC fluoro-
chrome, respectively.
Proteomic analysis on monocytes supernatants ex vivo
and in vitro
After thawing of PBMC samples collected from donors
enrolled in the HBV study, monocytes were derived
from immunomagnetic selection and cultured in vitro at
the concentration of 2 × 10
6 cells/ml in 2% human
serum-AIMV medium alone or supplemented with
HBsAg (10 μg/ml). 24 hours later, supernatants were
collected and frozen immediately. The presence of
CXCL-10 in the thawed supernatants was assessed by
Searchlight Assay (Pierce-Endogen), consisting of a mul-
tiplex array measuring several proteins per well in stan-
dard 96-well plates where different monoclonal
antibodies were spotted [33].
The same platform was used to detect the soluble fac-
tors released by monocytes isolated by healthy donors
and exposed in vitro for 24 hours to 1,000 U/ml of
IFNa2b (Intron A).
Statistical analyses
Mann-Whitney and Wilcoxon Matched pairs nonpara-
metric tests were used to investigate the significance of
differences in specific PBMC populations between
groups, as measured by citofluorimetry, for the proteo-
mic analysis of monocytes supernatants and for Real
Time PCR validation experiments.
Results
Signature of IFNa on human PBMC 24 hours after the
cytokine administration
As a first approach to analyze the data resulting from
the microarray experiments on the PBMC isolated from
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subjects receiving HBV vaccine plus IFNa (study 2, Fig-
ure 1C), the two complete data sets profiling each
17,000 genes were independently filtered to sort out the
most informative genes (80% gene presence across all
experiments and at least 3-fold ratio change). Unsuper-
vised hierarchical clustering obtained for the melanoma
patients data set resulted in 1,093 genes, and did not
segregate samples according to the IFNa plus peptide
treatment (data not shown), suggesting that the majority
of these transcripts were not dramatically affected by
the cytokine administration in vivo. Conversely, when
we performed a supervised hierarchical clustering
analysis on this same set of 1,093 genes in (Figure 1C),
grouping together samples collected at the time points
analyzed, the visual inspection of the resulting clustero-
gram identified two nodes of genes showing a dramatic
change in the level of expression after every peptides plus
IFNa treatment. In particular, the expression of these
genes was increased after the first administration of the
cytokine, was back to the basal level 42 days later and
increased again after the second IFNa administration.
The IFNa-specific nodes, highlighted in Figure 1B-D,
encompassed a signature of 68 transcripts, corresponding
to 55 known and 6 unknown genes. Unsupervised hier-
archical clustering analysis conducted on the data set of
Group A= placebo
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Figure 1 Signature of IFNa on human PBMC 24 hours after the cytokine administration. Treatment schedules for the clinical trials on
melanoma patients (A) and healthy donors (C) examined in this study (see Methods and Additional data file 1). (B) Clusterogram showing the
supervised hierarchical clustering of 6 PBMC samples collected before (T0, T42, blue bar) or after (T2, T44, red bar) the first and the fourth
administration of IFNa plus melanoma peptides. The analysis was restricted to the 1093 most informative transcripts among the 17,000 of the
complete dataset (80% gene presence across all experiments and at least 3-fold ratio change). (D) Clusterogram showing the supervised
hierarchical clustering of all samples collected before (T0, T1m, blue bar) or after (T0+24, T1m+24, red bar) the first and the second cycle of
administration of HBV vaccine in combination with placebo (black bar, group A), 1 (green bar, Group B) or 3 MU of IFNa (orange bar, Group C).
The analysis was restricted 1712 most informative genes (see above). The enlargements show the nodes of genes specifically up-regulated after
each IFNa plus vaccine administration.
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ing, resulted in 1,712 transcripts and in an characteristic
signature cluster of 57 transcripts (corresponding to 47
known and 4 unknown genes) strongly up-regulated after
every repeated administration of IFNa (Figure 1D). The
comparison of the two IFNa-signature lists thus gener-
ated showed that 41 genes were up-regulated in both
clinical settings 24 hours after the cytokine administra-
tion. This observation suggested that a signature of IFNa
administration in vivo on human PBMC could be
observed 24 hours after each consecutive cytokine
administration and showed a similar kinetic trend in mel-
anoma patients and healthy donors.
Consistency of IFNa-induced modulation of PBMC gene
expression profiles after each repeated administration of
the cytokine
We then moved to applying statistics to sort out the
most informative genes from the whole database, and
performed a class comparison analysis between the
groups of PBMC samples collected before and after the
treatment. For the study on melanoma patients, we initi-
ally focused on the first cycle of IFNa plus peptide
administration. One hundred and fifty-six genes were
significantly differentially expressed between T0 and T2
samples. Interestingly, when we let all samples available
from this study (T0, T2, T42, T44) cluster according to
the expression of these 156 genes, we obtained the seg-
regation of all samples collected before (T0,T42) from
samples collected after the treatment (T2, T44), regard-
less of the treatment cycle they belonged (Figure 2A).
This result suggested that the modulation of PBMC glo-
bal gene expression profile was consistently induced
after each repeated administration of the cytokine, and
was confirmed by reproducing the same phenomenon in
PBMC obtained during the fourth therapeutic cycle of
IFN administration in the melanoma study (Figure 2B).
In fact, when we analyzed the transcripts of this second
set of samples (T42, T44, collected 42 days after the
beginning of the study and 24 hours after IFNa admin-
istration respectively), we found 179 genes differentially
expressed between T42 and T44. Similarly to the tran-
scripts profiling of cycle 1, the unsupervised hierarchical
clustering of the complete database, based on the
expression of these 179 genes obtained from cycle 4
class comparison analysis, not only segregated T42 from
T44, but also separated T0 from T2 samples, with only
a few samples behaving as outliers (Figure 2B).
A similar result was observed in the profiling of HBV
specimens, for which a distinct segregation of all “pre”
from all “post” IFNa plus vaccine samples (T0, T1m vs
T0+24, T1m+24) could be obtained using either one of
the gene expression sets (from cycle 1 or cycle 2) found
to be significantly modulated by the HBV vaccine + 3MU
of the cytokine (T0 vs T0+24 or T1m vs. T1m+24, Figure
2C-D). The same pattern of segregation was obtained for
donors receiving 1MU of IFNa (data not shown)
Similarity of the modulation of PBMC gene expression
between two doses of IFNa tested
Taking advantage of the availability of blood samples
obtained from patients receiving two different doses of
IFNa, in the contest of the HBV study, we investigated
whether the exposure to different doses of the cytokine
caused a different modulation of PBMC gene expression.
To address this issue, we selected the genes most consis-
tently modulated by the cytokine by performing a class
comparison analysis between all “pre” vs all “post” samples
isolated from patients receiving 3 MU of IFNa. This class
comparison identified 161 differentially expressed genes.
Notably, the resulting gene list was not identical to the
176 gene list generated by comparing “pre” and “post” of
samples isolated from patients receiving 1 MU of IFNa,
since only 76 genes were overlapping (data not shown).
However, hierarchical clustering of all samples from
Group B (treated with 1 MU of IFNa) and C (treated with
3M Uo fI F N a), restricted to the levels of expression of
these 161 genes, showed that all “post” IFNa administra-
tion samples clustered together, whether they originated
from patients receiving 1 or 3 MU of the cytokine
(Figure 3A). The same result was obtained when the analy-
sis was restricted to the 176 genes differentially expressed
between all “pre” vs all “post” samples isolated from patients
receiving 1 MU of IFNa (group B): this clustering segre-
gated all “pre” from “post” samples, regardless of the dose
of IFNa administered together with the vaccine (Figure 3B).
Taken together, these observations suggest that the two
different doses of IFNa tested in our study gave rise to an
extent of gene expression modulation that was somewhat
similar. In particular, the trend of modulation achieved by
the two doses of the cytokine was not close enough to gen-
erate identical gene lists after statistical analysis. However it
was sufficiently similar to induce a similar change in PBMC
gene expression, so that all “pre” and “post” samples were
grouped together according to the intensity of expression
of these genes, regardless of their original treatment group.
As expected, blood samples isolated from patients
receiving placebo together with the HBV vaccine clustered
together with the “pre” samples according to the expres-
sion of these both sets of IFNa-induced genes, confirming
that these particular gene sets were more likely modulated
by the cytokine and not by the vaccine itself (Figure 3).
Genes up-regulated in the PBMC of humans receiving
IFNa are mainly involved in immune response-related
functions
In order to gain insights into the mechanisms of action of
IFNa administered in vivo,w ep e r f o r m e dt h ef u n c t i o n a l
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Page 6 of 15classification (based on Gene Ontology) of genes found
to be up-regulated or down-regulated by the cytokine in
human PBMC. In particular, the most consistently
modulated genes were selected by matching the gene list
obtained by the class comparison of all “pre” and “post”
IFNa administration samples in melanoma patients
(T0-T42 vs T2-T44, yielding to 311 genes) with that of
healthy donors vaccinated with HBV plus IFNa (T0-T1m
samples from groups B and C grouped together vs T0
+24h-T1m+24h samples from the same groups, yielding
T0+24h: Post HBV Vaccine + 3MU IFND 1C y c l e
T1m+24h: Post HBV Vaccine +3MU IFND 2nd Cycle
T44:Post Melanoma vaccine + IFND 4C y c l e
T2: Post Melanoma vaccine+ IFND 1C y c l e
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Figure 2 Consistency of IFNa-induced modulation of PBMC gene expression profiles after each repeated administration of the
cytokine. Dendrogram showing the unsupervised hierarchical clustering of all samples available for gene profiling analysis from the melanoma
and HBV study. For Melanoma study (A,B), the analysis was restricted to the 156 genes differentially expressed between T0 and T2 samples (A) or
the 179 genes differentially expressed between T42 and T44 samples (B). For HBV study (C, D), the analysis was restricted to the 249 genes
differentially expressed between T0 and T0+24 (C) of samples isolated from Group C patients (receiving 3MU IFNa), or to the 70 genes
differentially expressed between T1m and T1m+24 (D) of the same group. Blue bar: “pre” IFNa plus vaccine samples; red bar: “post” IFNa plus
vaccine samples; black bar: “pre” and “post” placebo plus vaccine samples.
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Figure 3 Similarity of the modulation of PBMC gene expression between two doses of IFNa tested in combination with the HBV
vaccine. Dendrogram of the unsupervised hierarchical clustering analysis of all samples collected in the HBV study. In (A) the analysis was
restricted to the expression of the 161 genes differentially expressed between all “pre” (T0, T1m) and all “post” (T0+24, T1m+24) samples isolated
from healthy donors receiving HBV vaccine in combination with 3 MU of IFNa (orange bar, Group C). In (B), the same analysis was conducted
on the 176 genes differentially expressed between all “pre” (T0, T1m) and all “post” (T0+24, T1m+24) samples isolated from donors receiving HBV
vaccine plus 1 MU of LE-IFNa (green bar, Group B). Blue bar: “pre” IFNa plus vaccine samples; red bar: “post” IFNa plus vaccine samples; black
bar: “post” placebo plus vaccine samples.
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Page 7 of 15to 487 genes). Figure 4 shows the biological process
classes of the in vivo IFNa modulated genes, ranked
according to the enrichment level of each class and com-
pared to the global composition of the array (modified
Fisher test p < 0.05). The blue bar represents the percen-
tage of genes modulated by IFNa belonging to each spe-
cific Gene Ontology category, and the purple bar
corresponds to the percentage of genes represented on
the array assigned to the same Gene Ontology category.
The results of this classification showed that the most
represented classes of the 130 up-regulated transcripts,
included genes involved in the response to virus or exter-
nal stimuli, immune-related genes, or genes involved in
the inflammation process (Figure 4A). The IFNa-induced
modulation of some of these genes, such as CXCL10,
BAFF and Mx, was confirmed by real time PCR (Addi-
tional data file 2).
Interestingly, a much lower level of consistency was
observed for the genes found to be down-regulated by
IFNa in vivo (Figure 4B), since for this category only 34
genes, mostly associate with general biosynthetic process
or gene expression Gene Ontology Categories, were
found to be in common between the two studies.
Consistency of IFNa signature in different in vivo and in
vitro settings
In the attempt to unravel the “core” signature of IFNa,
representative of the effect of this cytokine in vivo as
well as in vitro, we compared our microarray data on
PBMC obtained from subjects receiving IFNa in vivo
(study 1 and 2) with the profiling of transcripts
expressed by PBMC and monocytes exposed to IFNa in
vitro. To this end, total PBMC as well as purified CD14
+
monocytes isolated from five healthy donors were incu-
bated in vitro with IFNa2b, IFNg to control for IFNa
specific effects (10
3 IU/ml) or no stimulus for eight
hours. For ethical reasons, we could not collect more
blood samples from subjects enrolled in the clinical stu-
dies to perform the in vitro study. We first performed a
comparison among the transcripts of in vitro treated
PBMC, monocytes and respective controls. This analysis
resulted in a set of 376 transcripts for PBMC exposed to
IFNa (278 up-regulated and 98 down-regulated) and
304 transcripts for IFNa-treated monocytes (252 up-
regulated and 52 down-regulated). This gene lists were
then compared with the two lists of genes previously
found to be modulated by the cytokine in the two
0% 10% 20% 30% 40% 50%
1.6x 10-2
8.7x 10-4
Genes present on the array
Genes modulated by IFND
modified Fisher 
test p value
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Page 8 of 15clinical studies examined (all “pre” versus “post-IFNa”
samples for melanoma patients, yielding to 196 up-regu-
lated genes, and healthy subjects vaccinated with 1 or 3
MU of IFNa, yielding to 327 up-regulated genes). The
comparison of these 4 gene lists resulted in 74 tran-
scripts corresponding to 64 genes consistently up-regu-
lated after exposure to IFNa in all the settings
examined (Figure 5). Interestingly, although a few of
these genes showed a trend of increase also in mono-
cytes and PBMC exposed in vitro to IFNg, the induction
was much stronger in terms of log ratio levels and more
consistent among groups of samples treated with IFNa,
confirming that these 64 genes can be considered the
IFNa specific signature in human PBMC as well as
monocytes.
Enhanced transient expression of costimulatory molecules
and HLA-DR in CD14
+ and CD14
+/CD16
+ monocytes after
acute exposure to IFNa in healthy individuals
In order to further evaluate the effects of IFNa adminis-
tration in vivo, with particular focus on antigen present-
ing cell precursors, an immunophenotypic analysis was
performed by multicolor flow cytometry on PBMC
obtained from healthy subjects before and shortly after
HBV vaccine and IFNa administration. The results,
s h o w ni nF i g u r e6 ,p r o v i d e de v i d e n c et h a ta t2 4h o u r s
after the treatment the percentage of CD14
+ monocytes
in the whole PBMC populations was significantly higher
in both IFNa-treated groups (1 or 3 MU) (Figure 6A).
The IFNa administration also resulted in a significant
transient increase of the percentage of CD14
+ mono-
cytes expressing the costimulatory molecule CD40 as
compared to the administration of placebo (Figure 6B).
Monocytes isolated from IFNa-treated donors were also
endowed with a CD86 showing a higher mean fluores-
cence intensity (Figure 6C) and with a trend of increase
of the expression of HLA-DR (Figure 6D). No significant
increase of these molecules was detected by cytofluori-
metric analysis in the CD14
+ monocytes isolated from
the group of subjects receiving placebo together with
the HBV vaccine (Figure 6A-D).
A similar effect was found in cells expressing both
CD14 and CD16, reported to be more mature than
CD14 and showing features of tissue macrophages [34].
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Page 9 of 15In particular, the percentage of CD14
+/CD16
+ among
total donors PBMC increased after the first IFNa
administration was found back to basal level one month
later and rose again after the second treatment (Figure
6E). Also for these cells, the analysis showed an
increased expression of costimulatory molecules CD40
and CD86 and of HLADR after each IFNa administra-
tion (Figure 6F-H).
Release of chemotactic chemokines by monocytes
isolated from subjects exposed to IFNa
The induction of CXCL10 by IFNa, observed at a mole-
cular level by microarray analysis on PBMC, was further
investigated by performing a proteomic assay on super-
natants of CD14
+ monocytes isolated from healthy
donors receiving the cytokine in association with the
HBV vaccine. The results, reported in Figure 7, showed
that monocytes collected 24 hours after the administra-
tion of IFNa (1 or 3 MU) either sensitized in vitro with
the HBV specific antigen HBsAg (Figure 7A) or left
untreated as control (Figure 7B) had an increased ability
to release CXCL10 in the culture supernatants as com-
pared to pre-treatment samples or to samples of donors
receiving placebo. In particular, the kinetic of CXCL10
release during the first and second cycle of vaccination
resembled the trend of induction observed at the mRNA
level, with the samples collected one month after vacci-
nation showing basal levels of CXCL10, and a consider-
able raise 24 hours after each cytokine administration.
The pattern of soluble factors released by human
blood cells in response to IFNa was also evaluated in
the in vitro model of monocytes isolated from healthy
donors PBMC and exposed in vitro to IFNa2b, where
the significant release of CXCL10 was also observed,
together with the production of other 5 chemokines
(Additional data file 3).
Discussion
In the study presented herein, we applied microarray
technology to profile the gene expression in human
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Page 10 of 15PBMC treated in vivo with IFNa, administered at low
dose as vaccine adjuvant in the context of two separate
clinical trials, performed on melanoma patients and
healthy subjects, following a similar treatment schedule.
A clear-cut signature of IFNa in vivo could be observed
in human PBMC 24 hours after the cytokine administra-
tion in both clinical studies (Figure 1). Interestingly, the
modulation of PBMC global gene expression profile was
consistently induced after each repeated administration
of the cytokine, suggesting that, at least at the transcrip-
tional level, the extent of the modulations induced by
the cytokine is mainly transient, and does not reach a
steady state level refractory to further stimulations
(Figure 2). In general, the transcriptional modulations
observed appear quite homogeneous among the differ-
ent subjects analyzed, and no major differences between
groups of subjects receiving two different doses of the
cytokine were observed (Figure 3).
The results of our transcriptional profiling provided
the molecular basis supporting a predominant immuno-
modulatory role of IFNa when administered as vaccine
adjuvant. According to the gene ontology analysis
(Figure 4), the immunological pathways influenced by
IFNa in vivo recapitulate the progression of the main
steps for the generation of a specific immune response,
from the early non specific antiviral defense (OAS, MX),
to inflammation (TLR7, NMI, CXCL10, MYD88), recruit-
ment of immune cells (CXCL10, C3AR1, CX3CR1), anti-
gen processing and presentation (PSMB9, HLA-DOA) and
finally to the effectors specific immune response: (SERP-
ING1, C2, BST2, MYD88, TNFSF13B/BAFF).
Since PBMC is a heterogeneous population consisting
of various subsets of cells that may experience different
responses to IFNa, changes at the transcript level
observed in total PBMC specimens cannot be ascribed
to a specific immune effect. However, when we com-
pared human PBMC isolated after the in vivo adminis-
tration of the cytokine, to PBMC or purified monocytes
isolated from healthy donors and exposed in vitro to the
cytokine, we found a significant correlation among the
IFNa-up-modulated genes in the various group, so that
we were able to define a “core” IFNa signature consis-
tently observed in all the in vivo and in vitro settings
(Figure 5). Interestingly, among the genes consistently
up-regulated by IFNa associated with inflammation, we
found the metalloprotease MMP-1 not previously
reported to be an ISG (to the best of our knowledge),
and involved in extra cellular matrix degradation for
cells migration and tissue remodeling, during physiolo-
gical and pathological conditions [35]. Of interest,
MMP-1 can be released by macrophages, monocytes
[35] and monocyte-derived DC [36], and alteration of
its expression has been recently associated with auto-
immunity phenomena [36,37]. The “core” signature of
IFNa identified in our in vitro and in vivo experiments
also included BAFF, a gene showing a crucial role in B
cell maturation and activity, reported to be involved in
the pathogenesis of autoimmune diseases, such as
Rheumatoid arthritis, SLE and Progressive Systemic
Sclerosis in mouse models as well as in humans [38].
Moreover, our list included at least 4 genes belonging
to TLR7 pathway (Myd88, IRF7, CXCL10 and
STAT1), a system responsible for the activation of the
innate immune response in response to RNA viruses,
but also implicated in IFNa-related autoimmune phe-
nomena, mainly through plasmacytoid DC [39]. Inter-
estingly, TLR7 have been reported to be expressed by
IFN-DC, which could also secrete IFNa following viral
stimulation or TLR7-specific stimulation, thus con-
firming the critical role of this cytokine at the early
steps of immune response to pathogens or in autoim-
mune diseases [8].
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the results of different microarray studies is impaired by
the bias possibly induced by different platforms and sta-
tistical approaches, the core IFNa signature identified
by us in subjects receiving the cytokine as vaccine adju-
vant is not considerably different, in terms of modulated
genes and Gene Ontology categories, from the one
reported by studies investigating the same issue in
HCV-infected patients treated with IFN (IFNa2b or
PEG-IFNa2b) and Ribavirin [9-16]. Moreover, our data
on the transcriptional modulations observed in PBMC
treated in vitro with IFNa2b are concordant with data
reported by others on the effects on the same cells of
the pegylated form of the cytokine administered in asso-
ciation with Ribavirin [40]. Overall, these observations
strongly suggest that a similar signature occurs both in
vivo and in vitro (at least in PBMC), regardless of the
dose or type of IFNa used or even of the condition of
the subjects receiving the cytokine (healthy donors and
HCV-infected or cancer patients).
The proteomic analysis of the supernatants of mono-
cytes exposed in vitro to IFNa (Additional data file 3)
confirmed at the protein level the effect of this cytokine
on chemoattraction and inflammation observed at the
transcription level in vitro and in vivo, corroborating the
results of the gene ontology analysis on the immunomo-
dulatory role of IFNa in vivo. Although further studies
on specific cell subsets isolated ex vivo from subjects
receiving IFNa are needed to define the role of mono-
cytes in the cytokine activity in vivo, our results suggest
that monocytes contribute to the transcriptional modu-
lation seen on total PBMC, in line with previous obser-
vations from our group and others on IFNa linking
innate and adaptive immunity by affecting monocytes
differentiation into DC [reviewed in ref. [2]].
To gain more insight into the specific effects of IFNa
on the several monocytes blood populations, we ana-
lyzed the immunophenotype changes observed in PBMC
isolated from healthy donors before and after IFNa
administration, with particular focus on CD14
+ cells. Of
note, at the same time of detection of the typical IFNa
signature in PBMC, we also observed an increase in the
percentage of CD14
+ and CD14
+/CD16
+ monocytes,
and both cell populations proved to express high levels
of costimulatory molecules and HLA-DR (Figure 6).
Notably, such increase was transient, similarly to the
appearance of the IFNa signature, and additional rounds
of increase were observed at 24 hr after the subsequent
IFNa treatments, in parallel with the de novo detection
of an up-regulated expression of the typical IFNa-
induced genes.
CD14
+/CD16
+ monocytes, coexpressing CD16 and low
levels of CD14, were first characterized by Ziegler-
Heitbrock and colleagues in 1988 [41], and their number
and phenotype/function have been reported to be altered
in patients with cancer, infectious diseases or inflammatory
disorders [42-45]. Of note, an increase of CD14
+/CD16
+
monocytes was observed in patients infected with patho-
gens triggering IFNa production, such as certain bacteria
and HIV [45]. In general, this cell subset has been indi-
cated as a transitional stage of development of monocytes
to macrophages, originating from CD14
highCD16
+,o r
DC, derived from CD14
dimCD16
+ cells [46], and has been
shown to exhibit special capabilities to migrate [47], to
stimulate CD4
+ T cells [48] and to produce proinflamma-
tory cytokines [45]. Moreover, CD16
+ monocytes can dif-
ferentiate in CD1b
+ DC endowed with high APC capacity
after a short time exposure to TLR2 ligands [49], sup-
porting the concept that these cells may represent natural
precursors of DC in response to danger signals. In the
light of all this, it is possible that the transient up-regula-
tion of costimulatory molecules and HLA-DR in CD16
+
monocytes, occurring at the time of the appearance of a
PBMC IFNa molecular signature, characterized by
enhanced expression of immune-related cytokines/che-
mokines, can represent a reliable marker of the biologic
response to a local IFNa treatment, which may result in
the generation of active DC, resembling those naturally
generated from this monocyte subset in response to
infections and danger signals. Notably, an ensemble of
studies from our group and from other laboratories have
demonstrated that IFNa can induce a very rapid differen-
tiation of highly active DC from monocytes [50] and
these DC (IFN-DC) are characterized by a special signa-
ture [51], which partially overlaps with the IFNa-
signature described in the present study. In this regard, it
is worth mentioning recent results indicating that spon-
taneous regression of highly immunogenic Molluscum
contagiosum virus-induced skin lesions is associated with
the infiltration of DC strongly resembling IFN-DC [52],
supporting the concept that IFN-DC can indeed repre-
sent naturally occurring DC promptly generated in vivo
during the response to type I IFN induced by viruses and
other natural danger signals.
Of interest, a recent study by Mohty and colleagues [53]
has shown the increase of CXCL-10 plasma levels in mela-
noma patients treated with relatively low doses of IFNa,
which also parallels a trend towards an increase of CD16
+
monocytes. CXCL10 is an IFNa-induced chemokine,
which binds and activates the seven transmenbrane
G-protein-coupled receptor CXCR3, and is expressed
especially in activated Th1 cells, B cells, NK cells and DC,
thus suggesting that CXCL10 release can represent a pri-
mary event in the amplification of the IFNa response. The
results of Mohty and coworkers [53] are consistent with
our data showing an up-regulation of CXCL10 expression
after local low-dose IFNa injection, as revealed by
both genomic and proteomic analysis ex vivo and in vitro.
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Page 12 of 15Of note, the up-regulation of CXCL-10 has been reported
to occur also in HCV-infected patients shortly after the
administration of PEG-IFNa2b [8], so that it has been sug-
gested that CXCL-10 can represent a marker predictive of
the final treatment outcome [54].
Conclusion
Overall, the results presented herein show that: i) the
production of CXCL10 and a specific IFNa-signature
are observed in PBMC as early as 24 hr after cytokine
injection in healthy donors and melanoma patients; ii)
such response is transient, does not reach a steady-state
level of refractoriness and can occur after inoculation of
as little as 1 millions of units of IFNa. iii) The observed
molecular signature is paralleled by the raise in percen-
tage and expression of costimulatory molecules of CD14
+/CD16
+ peripheral blood cells, reported to be precur-
sors of DC in response to danger signals. These results
shed a new light on the immune mechanisms of action
of IFNa and, in particular, on the role of CXCL10 and
early effects of IFNa on monocyte/DC precursors (such
as CD14
+/CD16
+ cells) as primary players in the IFNa
response and stimulate further studies for identifying
molecular and biological markers capable of predicting
the clinical response to IFNa.
Additional material
Additional file 1: Complete treatment schedule of the clinical
studies examined and blood samples collection for gene profiling
analysis. (A) HLA-A*0201
+ stage IV metastatic melanoma patients
underwent four cycles of vaccinations with gp100:209-217(210M),
IMDQVPFSV and Melan-A/MART-1 Melan-A/MART-1:26-35(27L),
ELAGIGILTV melanoma peptides (white arrows), given in combination
with 3 MU of IFNa (grey arrows) administered the previous day, in
concomitance and the following day of the peptides inoculation. For
gene profiling analysis on PBMC, blood was collected before (T0 and
T42) and 24 hours after the IFNa plus peptide administration (T2 and
T44) (Blue arrows). PBMC collections for gene profiling coincided with
the first and the fourth vaccination. (B) Healthy subjects were randomly
divided into three groups to receive the HBV Engerix-B vaccine (white
arrows) plus saline placebo or the HBV vaccine (grey arrows) in
association with human leukocyte IFNa (Alfaferone) at the dose of 1 or 3
MU. The vaccination course was the standard 3-dose regimen
administered at time zero (T0, baseline), one and six months later (T1
and T6m), in the placebo group, and two doses at T0 and T1m in the
IFNa-treated groups. For gene profiling analysis on PBMC, blood samples
were collected from 10 subjects per group before (T0, T1m) and 24
hours after the placebo or IFNa plus vaccine administration (T0+24, T1m
+24), and the collection was repeated on the first and the second cycle
of vaccination.
Additional file 2: Real time PCR validation of microarray data. Real
Time PCR validation of the expression of BAFF (A, B), CXCL10 (C, D) and
Mx (E, F) transcripts in samples collected at different time points during
the melanoma (a, c, e) and HBV (b, d, f) studies. The box plot graph
shows cDNA copies for each gene, normalized by the copies of Beta
Actin as housekeeping, measured for five samples per group. Red line:
Mean, Black line: Median, Box: 25
th to 75
th percentile, whiskers:10
th to
90
th percentile. * p < 0.05 (Wilcoxon Matched Pairs test).
Additional file 3: Release of chemotactic chemokines by CD14
+
monocytes exposed to IFNa in vitro. Chemotactic chemokines
released by monocytes isolated from healthy donors and exposed in
vitro to 10
3IU/ml of IFNa. The graph shows the 6 factors selected, out of
a panel of 46 tested, for being significantly enriched in the supernatants
of cells exposed to the cytokine as compared to untreated controls. The
box plot graph shows for 10 samples per group: Red line: Mean, Black
line: Median, Box: 25
th to 75
th percentile, whiskers:10
th to 90
th percentile.
*p < 0,005,
§p < 0,05 (Wilcoxon Matched Pairs test).
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